CD7 CAR-T cells
- Generic Name
- CD7 CAR-T cells
CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases
- Conditions
- Bone Marrow Failure Syndrome
- Interventions
- Procedure: Allo-HSCT
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06787560
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
- Conditions
- Schimke Immuno-osseous Dysplasia
- Interventions
- First Posted Date
- 2025-01-10
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 20
- Registration Number
- NCT06769191
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
- Conditions
- Aplastic Anemia
- Interventions
- Other: Allogeneic hematopoietic stem cell transplantation
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 30
- Registration Number
- NCT06633328
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou, Zhejiang, China
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- The General Hospital of Western Theater Command
- Target Recruit Count
- 200
- Registration Number
- NCT06585345
- Locations
- 🇨🇳
The General Hospital of Western Theater Command, Chengdu, Sichuan, China
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
- Conditions
- T-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies
- Interventions
- Drug: Prior-HSCT donor-derived CD7 CAR T-cellDrug: New donor-derived CD7 CAR T-cell
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Beijing GoBroad Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06316427
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
🇨🇳Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai, China
🇨🇳Shanghai Liquan Hospital, Shanghai, Shanghai, China
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
- Conditions
- Hematologic DiseasesNeoplasms
- Interventions
- Other: Allogeneic hematopoietic stem cell transplantation
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 30
- Registration Number
- NCT05827835
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.